Digimed and diagnostics: Market access and new collaborations

April 6, 2017 Christoph Graener

The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on the interactions between patients and their healthcare providers and between the healthcare system and its service and support providers. While these changes herald more streamlined and to some extent personalized treatments for patients, the dynamic of these relationships will also have profound effects on treatment decisions. We examine the factors digital medicine companies face in gaining market access.

Moderator: Josep Sanfeliu – Ysios Capital
Michäel Herman – OncoDNA
Jeremy Sohn – Novartis
Gregg Talbert – Roche Partnering

 

Previous Article
Biomunex CEO on earlier deals for cancer drugs

Biomunex CEO Pierre-Emmanuel Gerard discusses the company's pipeline of innovative bispecific antibodies be...

Next Article
Stirring the entrepreneurial pot in Europe

Europe has many of the biggest pharma companies and best academic biomedical researchers. What is happening...